Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350714 · ClinicalTrials.gov registry record · Phase 2
BreathID Multi-center HCV Liver Breath Test Study
A Phase 2 study, sponsored by Meridian Bioscience.
- Terminated
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00350714 is a Phase 2 study that was terminated before completion, run by Meridian Bioscience. The registered enrollment target is 75 participants.
The verdict
NCT00350714, a Phase 2 study, was terminated before completion, sponsored by Meridian Bioscience.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The goal of this study is to validate the BreathID 13C-methacetin breath test (MBT) as a non-invasive simple-to-use metabolic test, which could be utilized to detect severe liver fibrosis (\>2 in METAVIR) in patients with chronic HCV liver disease.The test is a breath-test using a free-standing device (BreathID®) that measures metabolization of a 13C-labeled substrate (13C-methacetin) in real time.
Interventions
- OTHER MBT and BreathID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350714
The ClinicalTrials.gov registry entry for NCT00350714 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MBT and BreathID is the first listed.
NCT00350714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350714 about?
NCT00350714 is a clinical study titled "BreathID Multi-center HCV Liver Breath Test Study". The goal of this study is to validate the BreathID 13C-methacetin breath test (MBT) as a non-invasive simple-to-use metabolic test, which could be utilized to detect severe liver fibrosis (\>2 in METAVIR) in patients with chronic HCV liver disease.The test is a breath-test using a free-standing devi...
What is the current status of trial NCT00350714?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2006-07. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00350714?
The interventions under investigation include: MBT and BreathID (OTHER).
Who is sponsoring clinical trial NCT00350714?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.